The company had received FDA approval for the launch in December.
The tablets has annual sales of approximately USD 22 million in the US.
Lupin’s product will be called Tydemy.
The combination is indicated for use by women to prevent pregnancy and to raise folate levels in women who choose to use an oral contraceptive for contraception, Lupin said.
The combination involves Drospirenone, Ethinyl Estradiol, and Levomefolate Calcium Tablets in doages of 3 mg, 0.03 mg and 0.451 mg and Levomefolate Calcium Tablets, 0.451 mg.
Lupin is the 6th largest generics pharmaceutical company by revenue.